Lipocine director granted 1,764 stock options

Ono Richard Dana reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Ono Richard Dana reported acquisition or exercise transactions in this Form 4 filing.

Lipocine Inc. director Richard Dana Ono received an equity award in the form of derivative rights to buy 1,764 shares of Common Stock at $2.19 per share. This grant is a compensation-related award, not an open-market purchase or sale. The rights vest 100% one year from the grant date and are exercisable until June 3, 2036. After this award, Ono holds derivative rights covering a total of 13,290 shares of Lipocine common stock directly.

Insider Trade Summary

Grant/Award: 1,764 shares

Grant/Award 1 txn

Insider Ono Richard Dana

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock (Right to Buy)	1,764	$2.19	$4K

Holdings After Transaction: Common Stock (Right to Buy) — 13,290 contracts (Direct)

Footnotes (1)

1. F1. 100% vesting one year from date of grant.

Key Figures

Award size: 1,764 shares Exercise price: $2.19 per share Post-award derivative holdings: 13,290 shares +2 more

5 metrics

Award size 1,764 shares Derivative rights to buy Lipocine common stock

Exercise price $2.19 per share Strike price for 1,764-share award

Post-award derivative holdings 13,290 shares Total derivative rights following this grant

Vesting schedule 100% after 1 year All 1,764 shares vest one year from grant

Expiration date June 3, 2036 Expiration of the derivative award

Key Terms

Common Stock (Right to Buy), Grant, award, or other acquisition, vesting, expiration date

4 terms

Common Stock (Right to Buy) financial

"security_title: "Common Stock (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

vesting financial

"footnote: "100% vesting one year from date of grant.""

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

""expiration_date": "2036-06-03T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lipocine (LPCN) director Richard Dana Ono report on this Form 4?

Richard Dana Ono reported receiving a grant of derivative rights to buy 1,764 shares of Lipocine common stock at $2.19 per share. This is a compensation-related equity award, not an open-market stock purchase or sale.

How many Lipocine (LPCN) shares are covered by the new award?

The new award covers 1,764 shares of Lipocine common stock. These are derivative rights to buy shares in the future, subject to vesting and exercisable at a fixed price of $2.19 per share.

What is the exercise price and term of the Lipocine (LPCN) award?

The derivative award gives Richard Dana Ono the right to buy 1,764 Lipocine shares at $2.19 per share. The rights are exercisable until June 3, 2036, providing a long-term incentive aligned with the company’s performance.

When do Richard Dana Ono’s new Lipocine (LPCN) rights vest?

The award vests 100% one year from the grant date. That means all 1,764 underlying shares become exercisable together after this one-year vesting period, according to the disclosed footnote in the Form 4.

How many Lipocine (LPCN) derivative rights does Richard Dana Ono hold after this grant?

After this grant, Richard Dana Ono holds derivative rights covering 13,290 Lipocine common shares directly. This total includes the newly awarded 1,764-share grant reported in the Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ono Richard Dana

(Last) (First) (Middle)

C/O 675 ARAPEEN DR

SUITE 202

(Street)

SALT LAKE CITY UTAH 84108

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lipocine Inc. [ LPCN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock (Right to Buy)	$2.19	06/03/2026		A		1,764		06/03/2027(1)	06/03/2036	Common Stock	1,764	$2.19	13,290	D

Explanation of Responses:

1. 100% vesting one year from date of grant.

	/s/ Richard Dana Ono	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)